Menu
Menu
Cipla and Alkem Laboratories are poised to acquire a controlling stake in Sahajanand Medical Technologies, India's leading cardiac stent manufacturer, with a deal valued between Rs 3,500 and Rs 4,000 crore. As major private equity firms step back, this acquisition could reshape the competitive landscape of the expanding cardiac stent market. The Kotadia family plans to retain a minority stake, while SMT explores IPO options following a pause in its previous listing plans. Dive into the details of this high-stakes negotiation and its potential impact on the future of cardiac care in India